Aucubin is a widely distributed iridoid glycoside that has gained increasing attention as a multifunctional scaffold in natural product-based drug discovery. Occurring predominantly in Plataginaceae and related medicinal plant families, aucubin is biosynthesized through a modified monoterpenoid pathway and stored as a stable glycoside that undergoes enzymatic activation to yield its aglycone aucubigenin. This prodrug-like behavior underlies its context-dependent biological activity. Accumulating preclinical evidence demonstrates anti-oxidant, anti-inflammatory, anti-fibrotic, metabolic-regulatory, cytoprotective, and immunomodulatory effects across models of cardiovascular disease, diabetes, chronic kidney injury, liver fibrosis, neurodegeneration, respiratory disorders, osteoporosis, wound healing, and cancer. Mechanistically, aucubin consistently modulates convergent stress-response pathways, including suppression of NF-κB signaling, activation of Nrf2/ARE anti-oxidant defense, regulation of AMPK-mediated metabolic homeostasis, preservation of mitochondrial integrity, and inhibition of TGF-β/Smad-driven fibrogenesis. In bone and metabolic disorders, aucubin restores redox balance and supports osteoblast function while limiting osteoclastogenesis. In cancer models, it suppresses proliferation and modulates tumor-associated immune signaling, including PD-L1 expression. These pathways are central to the global burden of non-communicable diseases, directly aligning aucubin research with Sustainable Development Goal 3 (Good Health and Well-being). While the breadth and internal consistency of experimental findings support its value as a multi-target cytoprotective template, translation toward clinical application remains limited by the scarcity of human studies, standardized pharmacokinetic data, and comprehensive toxicological evaluation. Collectively, this review positions aucubin as a biologically informative iridoid glycoside with substantial scaffold-level relevance for future natural-product-inspired therapeutic development, rather than as a near-term clinical drug candidate.
M. Arafat, Mostafa K. Mohammad, Kareem A. Attallah et al.· European Journal of Pharmaco...· 0 citations
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral disturbance, largely associated with amyloid-β accumulation, tau protein pathology, synaptic dysfunction, oxidative stress and neuroinflammation. Previous research emphasizes the critical roles of impaired neurogenesis and neuroplasticity in cognitive dysfunction and neurodegenerative disorders, particularly AD. This review highlights the therapeutic potential of natural products in restoring these processes. It offers a comprehensive overview of the molecular mechanisms underlying neurogenesis and synaptic plasticity, with a focus on key regulatory pathways, such as BDNF/TrkB, ERK/CREB, PI3K/Akt and neurotransmitter signaling cascades. It also shows how the disruption of these regulatory pathways, caused by AD-associated pathological factors, results in reduced neuronal regeneration and synaptic connectivity. Furthermore, it summarizes preclinical data showing that various phytochemical compounds, such as ginsenosides, epigallocatechin gallate, curcumin, resveratrol, and flavonoids can improve neural stem cell proliferation, promote neuronal differentiation, and enhance synaptic function. Despite the promising pre-clinical studies results, clinical studies evaluating natural products remain limited due to poor bioavailability, inconsistent efficacy, and methodological constraints in human studies. To overcome these limitations, new strategies such as nanotechnology-based delivery systems and advanced brain targeting approaches are being developed. Overall, natural products represent promising candidates for managing neurogenesis and neuroplasticity in AD, although further clinical studies are required to validate their therapeutic efficacy.
A. Shaheen, Mou-Sa A. Mai, Merhan O. Hindam et al.· Frontiers in Pharmacology· 2 citations
The RH1 actinobacterial consortium efficiently degraded glyphosate, fitting best to the Haldane–Andrews kinetic model, highlighting RH1’s potential for bioremediation of glyphosate-contaminated soils.
Hadjer Rebai, Rym Salah-Tazdaït, Djaber Tazdaït et al.· Frontiers in Bioengineering...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
